ClinicalTrials.gg
CompletedNCT03033342Updated Nov 9, 2023

Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4

A Phase 1 interventional study of Oral single doses of MRX-4 and Oral multiple doses of MRX-4 in Safety, sponsored by MicuRx. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by MicuRx · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2016, registered Dec 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A phase one study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. Cohorts of healthy adults (female and male) will participate in:

single dose escalation study of increasing doses of MRX-4 given by mouth others will participate in multiple dose escalation cohorts of MRX-4 given twice daily by mouth.

other cohorts of subjects will participate in the study to evaluate the impact of concomitant food or Omeprazole on safety, tolerability and pharmacokinetics of MRX-4

02

Conditions studied

  • Safety

Keywords

  • Phase 1
03

In context

Lead sponsor

MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects

Exclusion criteria

Exclusion Criteria:

  • Underlying hepatic, renal, metabolic, hematologic, cardiovascular, or immunologic disorder
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Oral single doses of MRX-4

    Single escalating oral doses of MRX-4 from 250 mg to 3000 mg

    Drug: Oral single doses of MRX-4

  • Experimental
    Oral multiple doses of MRX-4

    Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg

    Drug: Oral multiple doses of MRX-4

  • Experimental
    MRX-4 co-administered with omeprazole

    Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.

    Drug: MRX-4 co-administered with omeprazole

  • Placebo comparator
    Oral single doses of placebo

    Single oral doses of placebo to match MRX-4

    Drug: Oral single doses of placebo

  • Placebo comparator
    Oral multiple doses of placebo

    Multiple oral doses of placebo given twice daily for 10 days to match MRX-4

    Drug: Oral multiple doses of placebo

  • Placebo comparator
    Placebo co-administered with omeprazole

    Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole

    Drug: Placebo co-administered with omeprazole

Interventions

  • DrugOral single doses of MRX-4

    Oral single escalating doses of MRX-4

  • DrugOral multiple doses of MRX-4

    Multiple ascending doses of MRX-4 given twice daily for 10 days

  • DrugMRX-4 co-administered with omeprazole

    Drug page: OmeprazoleStudies of OmeprazoleOmeprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7

  • DrugOral single doses of placebo

    Single doses of placebo to match MRX-4

  • DrugOral multiple doses of placebo

    Oral placebo given twice daily for 10 days to match the oral MRX-4

  • DrugPlacebo co-administered with omeprazole

    Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7

06

What researchers measure

Primary outcomes

  1. Safety of single and multiple ascending doses of MRX-4

    Summary of number of subjects with changes in vital signs, physical examinations, clinical lab data, ECG parameters and adverse events

    Time frame: Screening through end of study visit on Day 7 (Part 1), Day 17 (Part II) and Day 14 (Part III)

  2. Summary of concentration time data for MRX-4 and its metabolites

    Concentration time data for MRX-4 and its metabolites in blood and urine

    Time frame: Pre-dose through 72 hours post dose

Secondary outcomes

  1. Summary of the plasma concentration teim data for MRX-4 under fed or fasted conditions

    Concentration time data for MRX-4 and its metabolites in blood and urine under fed and fasted conditions

    Time frame: Pre-dose through 72 hours post dose

  2. Safety of MRX-4 co-administered with omeprazole

    Summary of the number of subjects with changes in vital signs, physical examinations, clinical lab data, ecg parameters and adverse events

    Time frame: Screening through end of study on Day 14

  3. Summary of the plasma concentration time data for MRX-4 co-administered with omeprazole

    Concentation time data for MRX-4 and its metabolites in blood and urine with and without omeprazole

    Time frame: Pre-dose through 72 hours post dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The study results will be published in the future

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Feb 2017, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Jan 26, 2017
StartActual
Aug 2, 2016
Primary completionActual
Feb 1, 2017
CompletionActual
Feb 1, 2017
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03033342
Lead sponsor
MicuRx
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Aug 2, 2016
Primary completion
Feb 1, 2017
Completion
Feb 1, 2017
Last update
Nov 9, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion